Objective: Because OxPAPC exhibits long-lasting anti-inflammatory and lung-protective effects even after single administration in vivo, we tested the hypothesis that these effects may be mediated by additional mechanisms, such as OxPAPC-dependent production of anti-inflammatory and proresolving lipid mediator, lipoxin A4 (LXA4). 
T he vascular endothelium forms a selective permeable barrier and participates in the regulation of macromolecule transport and blood cell trafficking through the vessel wall. Control of vascular endothelial cell (EC) barrier is achieved via a balance of barrier-disruptive and barrier-protective signals from circulating bioactive molecules, bacterial and viral pathogens, mechanical microenvironment, and other factors.
Circulating and tissue levels of oxidized phospholipids may become rapidly elevated in a variety of pathological conditions accompanied by oxidative stress, including autoimmune diseases, lung injury, and sepsis. 1 Inflammation-induced generation of oxidants leads to formation of fatty acid hydroperoxides and further accumulation of fragmented and full length oxidized products in cell membranes and lipoproteins. One of the major plasma membrane phospholipids containing polyunsaturated fatty acids is 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC). Generation of oxidized PAPC (OxPAPC) is a result of oxidation of sn-2 unsaturated groups in arachidonic acid contained in the PAPC structure, which leads to formation of full length and fragmented OxPAPC species. 1, 2 OxPAPC enriched in full length oxygenated fatty acid residues causes sustained EC barrier-enhancing effect mediated by activation of Rap1 and Rac1 GTPases, remodeling of cortical actin cytoskeleton, and enhancement of EC junctions. [3] [4] [5] OxPAPC also protects against EC barrier dysfunction and vascular leak caused by edemagenic agonists or excessive mechanical stretch via Rap1/Rac1-dependent downregulation of barrier-disruptive RhoA signaling.
In acute settings, OxPAPC also exhibits potent anti-inflammatory effects. In the model of lipopolysaccharide-induced acute lung injury, OxPAPC decreases inflammatory cell recruitment and cytokine production in the lungs 6, 8, 9 and even protects against lipopolysaccharide-mediated lethal shock by blocking the lipopolysaccharide-TLR4 (Toll-like receptor 4) inflammatory cascade. 10 Additional anti-inflammatory mechanism of OxPAPC is inhibition of RhoA-dependent stimulation of p38 MAPK (mitogen-activated protein kinase) and NF (nuclear factor)-κB inflammatory pathways. 11 As a result, OxPAPC-induced inhibition of TLR-NF-κB inflammatory cascade and potent barrierenhancing effect preventing vascular leak and lung infiltration of inflammatory cells lead to immediate blockade of inflammatory response in the lung. 8, 9 A remarkable feature of OxPAPC anti-inflammatory action is its sustained effect in vitro and in vivo, even in the setting of OxPAPC post-treatment. 11 These observations suggest a possible involvement of other mechanisms contributing to OxPAPC anti-inflammatory properties.
Progression of inflammatory process is associated with a phenomenon called lipid program switch, where production of proinflammatory lipid molecules (thromboxanes, leukotriens, etc) in the early phase of inflammation is switched to production of lipid mediators with anti-inflammatory properties (lipoxins and resolvins) which suppress inflammation and promote resolution phase. [12] [13] [14] Lipoxin A4 (LXA4) belongs to a group of lipid mediators generated later in the course of acute lung injury and contributing to resolution of inflammation. 12, 15 Formyl peptide receptors (FPRs) are G protein-coupled receptors known to be important in host defense and inflammation. The 3 human FPRs (FPR1, FPR2/ALX, and FPR3) share significant sequence homology and are encoded by clustered genes. 16 These receptors bind a structurally diverse group of Nformyl and nonformyl peptides of bacterial and mitochondrial origin with N-formylmethionine as the only ligand class common to all 3 human receptors. High-affinity binding of LXA4 to FPR2/ALX 17 defines its anti-inflammatory and proresolution effects in various models of innate immune response. [18] [19] [20] The current study tested the hypothesis that pronounced and sustained anti-inflammatory effects of OxPAPC may involve induction of LXA4 production by pulmonary EC. The role of this mechanism was investigated using biochemical and molecular approaches in cell and animal models, including genetic model of lipoxin receptor mFPR2 −/− (mouse formyl peptide receptor 2) mice.
Methods

Reagents and Cell Culture
PAPC and oxidation-resistant 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) were obtained from Avanti Polar Lipids, Alabaster, AL. PAPC was oxidized by exposure of dry lipid to air as previously described. [21] [22] [23] The extent of oxidation was monitored by positive ion electrospray mass spectrometry (MS) as described previously. 23 
Novelty and Significance
What Is Known?
• Oxidative stress accompanies tissue injury, infection, and sepsis and elevates circulating and tissue levels of oxidized phospholipids.
• Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC) exhibits long-lasting anti-inflammatory and vascular protective effects in acute lung injury even after single administration in vivo.
• Products of PAPC oxidation attenuate the innate immune response via antagonistic effects on Toll-like receptors and reduce endothelial permeability by suppressing the RhoA GTPase signaling.
What New Information Does This Article Contribute?
• Exposure of endothelial cells to oxidized PAPC, but not to nonoxidized phospholipids, induces time-dependent generation of the proresolving mediator lipoxin A4.
• Anti-inflammatory effects of oxidized PAPC were attenuated in vitro and in vivo by inhibition of the lipoxin A4 receptor, formyl peptide receptor-2/ALX.
This study demonstrates for the first time alternative protective mechanisms triggered oxidized PAPC in the models of lung inflammation and endothelial dysfunction caused by inflammatory agents. We show that injury-associated generation of phospholipid oxidation products triggers the production of antiinflammatory lipid mediators, such as lipoxin A4, which may represent a built-in mechanism of vascular and tissue auto recovery after injury. 
Measurements of Endothelial Monolayer Permeability
The cellular barrier properties were analyzed by measurements of transendothelial electric resistance (TER) across confluent human pulmonary artery endothelial monolayers using an electric cell-substrate impedance sensing system (Applied Biophysics, Troy, NY) as previously described. 24, 25 Analysis of EC permeability for macromolecules was performed using Vascular Permeability Imaging Assay (express permeability testing assay; Millipore, Bellerica, MA) as described elsewhere.
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Immunofluorescence Staining
After agonist treatment, ECs grown on glass cover slips were fixed in PBS containing 3.7% formaldehyde, and F-actin was visualized by immunofluorescence staining of cell monolayers with Texas Redconjugated phalloidin. Adherens junctions were labeled with antibodies against vascular endothelial cadherin, as previously described. 27, 28 siRNA Transfection of EC Cultures Pulmonary EC were treated with gene-specific small interfering RNA (siRNA) duplexes. Pre-designed human Stealth Select siRNA sets of standard purity were ordered from Invitrogen (Carlsbad, CA), and transfection of EC with siRNA was performed as previously described. 29 The siRNA transfection efficiency according to our protocol exceeded 90%.
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Quantitative Reverse Transcription Polymerase Chain Reaction
Analysis of FPR1, FPR2/ALX, FPR3, 15-lipoxygenase, and ICAM1 mRNA expressions by human pulmonary EC was performed by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR). Gene expression fold changes were calculated according to the ΔΔCt method.
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Immunoblotting
Western Blot analysis was performed as described elsewhere. 32 Protein extracts were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and the membranes were incubated with antibodies of interest. Equal protein loading was verified by probing of membranes with antibody to β-tubulin.
ELISA Analysis
Concentrations of TNFα and soluble ICAM1 in control and treated cell-conditioned medium samples were measured using ELISA kit available from R&D Systems (Minneapolis, MN) according to manufacturer's instructions. LXA4 detection in EC-conditioned medium and lung tissue samples was performed after solid phase extraction using ELISA kit from Oxford Biomedical Research (Oxford, MI, cat no. EA45). Absorption was measured using a 2030 Multylabel Reader Victor X5 (Perkin Elmer).
Animal Studies
All experimental protocols involving the use of animals were approved by the University of Chicago Institutional Animal Care and Use Committee for the humane treatment of experimental animals. mFPR2 −/− mice have been previously described. 33 C57Bl6 mice used in this study were anesthetized with an intraperitoneal injection of ketamine (75 mg/kg) and acepromazine (1.5 mg/kg). Bacterial lipopolysaccharide (lipopolysaccharide, 0.7 mg/kg body weight; Escherichia coli O55:B5) was injected intratracheally in a small volume (20-30 µL) . OxPAPC (1.5 mg/kg) or sterile saline solutions were administrated 5 hours after lipopolysaccharide instillation by intravenous injection in the external jugular vein. Animals were euthanized by exsanguination under anesthesia 24 hours after lipopolysaccharide challenge and used for evaluation of lung injury parameters.
Evaluation of Lung Injury Parameters
Collection of bronchoalveolar lavage (BAL) fluid was performed using 1 mL of sterile Hanks' balanced saline buffer. The BAL protein concentration was determined by BCA™ (bicinchoninic acid) Protein Assay kit (Thermo Scientific, Pittsburg, PA). BAL inflammatory cell counting was performed using a standard hemacytometer technique. 34 As an additional parameter reflecting increased lung vascular leakiness, Evans blue accumulation in the lung tissue was evaluated as described previously. 34 At the end of the experiment, thoracotomy was performed, and the lungs were perfused in situ via the left atrium with PBS containing 5 mmol/L EDTA to flush the blood off the lungs. Left lung and right lungs were excised and imaged by a Kodak digital camera.
Statistical Analysis
Results are expressed as means±SD. Experimental samples were compared with controls by unpaired Student t test. For multiplegroup comparisons, a 1-way ANOVA and post hoc multiple comparison tests were used. P<0.05 was considered statistically significant.
Results
Lipoxin receptors are expressed in pulmonary EC but do not affect OxPAPC-induced barrier-enhancing effects on endothelial barrier.
The levels of mRNA expression of FPR family members FPR1, FPR2/ALX, FPR3 were evaluated by quantitative RT-PCR and showed comparable expression of all 3 receptors ( Figure 1A ). Involvement of FPR receptors in barrier-enhancing effects of OxPAPC was tested by measurements of TER reflecting barrier property of EC monolayer. Selective knockdown of each FPR receptor was performed using gene-specific siRNA. Experiments with selective knockdown of FPR1, FPR2/ALX, and FPR3 receptors showed no effect on OxPAPC-induced TER increase ( Figure 1B ). Knockdown efficiency of FPRs was verified by quantitative RT-PCR. In additional studies, we used 2 FPR peptide inhibitors: WRW4 (2.5 and 5 µmol/L; Figure 1C ) and Boc-FLFLF (10, 20, and 40 µmol/L; Figure 1D ). None of these treatments affected OxPAPC-induced sustained increase in TER. These data suggest that FPR receptors do not mediate barrier-enhancing effects of OxPAPC. Immunofluorescence staining of OxPAPC-stimulated EC monolayers (Online Figure I ) showed increased vascular endothelial cadherinpositive areas at the cell-cell junctions, as well as dissolution of central actin stress fibers and pronounced peripheral localization of F-actin. These morphological changes reflect enhancement of adherens junctions and peripheral cytoskeleton underlying increased barrier properties of OxPAPC-stimulated EC monolayer. Pre-treatment with Boc-FLFLF had no effect on basal adherens junctions and cytoskeletal arrangement or OxPAPC-induced cytoskeletal remodeling.
FPR receptors are not involved in OxPAPC barrier-protective effects against thrombin.
Stimulation of pulmonary EC with thrombin induces rapid and reversible permeability increase mediated by RhoA GTPase activation and MLC phosphorylation. 35 Effects of FPRs knockdown were evaluated in fluorimetry-based permeability assay for macromolecules in 96-well plates described in Methods. Thrombin-induced increase in EC permeability was suppressed by EC cotreatment with OxPAPC. This protective effect of OxPAPC was not affected by siRNA-induced knockdown of FPR1, FPR2/ALX, or FPR3 ( Figure 2A ).
Thrombin-induced MLC phosphorylation associated with increased permeability was significantly attenuated by OxPAPC pre-treatment, and this protective effect was not influenced by knockdown of FPR1, FPR2/ALX, or FPR3 ( Figure 2B ). In line with lack of FPR involvement in EC barrier protection against agonist-induced permeability, pre-treatment of thrombin-stimulated pulmonary EC with FPR2/ALX ligand, LXA4, did not affect thrombin-induced MLC phosphorylation ( Figure 2C ). In turn, OxPAPC suppressed thrombin-induced MLC phosphorylation, as we have described before. 6, 7 OxPAPC Attenuates TNFα-Induced EC Inflammatory Activation
OxPAPC abolishes EC inflammation and barrier dysfunction caused by lipopolysaccharide: (1) via induction of LXA4 production (this study); (2) inhibition of lipopolysaccharideinduced activation of TLR4 receptor; and (3) by direct stimulation of barrier function of inflamed endothelium via Rac1/ Rap1-dependent cytoskeletal remodeling. 7, 10, 29 TNFα is another potent activator of EC inflammation and sustained barrier dysfunction 36, 37 acting in a TLR4-independent manner. Therefore, to dissect TLR4 antagonism and TLR4-independent anti-inflammatory mechanisms, we stimulated cultured cells with TNFα. Activation of NF-κB-mediated inflammatory signaling cascade by TNFα was reflected by TNFα-induced degradation of NF-κB inhibitory subunit, IκBα. This effect was attenuated by pre-treatment with OxPAPC. Pre-treatment with LXA4 caused similar effect and prevented degradation of NF-κB by TNFα ( Figure 3A, top) . LXA4 exhibited dosedependent anti-inflammatory effects that were saturated between 10 and 100 nmol/L (Online Figure II) . These data are consistent with dose-dependent increase of LXA4 inhibitory effect on TNFα-induced NF-κB activation, neutrophil migration, 38 and inhibition of neutrophil-endothelial interactions. 39 Inflammatory activation of vascular endothelium by TNFα also stimulates NF-κB-dependent expression of adhesion molecules ICAM1 and VCAM1. These EC receptors are involved in neutrophil adhesion to the vascular EC, leading to neutrophil transmigration to the lung parenchyma and development of lung inflammation. In agreement with inhibition of NF-κB signaling, TNFα-induced expression of ICAM1 and VCAM1 was abolished in EC pre-treated with OxPAPC or LXA4 ( Figure 3A , bottom). Complementary quantitative RT-PCR analysis showed strong upregulation of ICAM1 mRNA expression caused by TNFα, which was attenuated by OxPAPC and LXA4 ( Figure 3B ). OxPAPC and LXA4 also attenuated TNFα-induced secretion of soluble ICAM1 to the culture medium detected by ELISA assay ( Figure 3C ).
FPR2/ALX Mediates Protective Effects of OxPAPC Against TNFα-Induced EC Barrier Dysfunction and Inflammatory Activation
In contrast to rapid and reversible EC permeability response to thrombin, EC challenge with TNFα causes sustained EC barrier dysfunction associated with activation of inflammatory signaling pathways. 37 Analysis of permeability for fluorescein isothiocyanate-avidin in EC monolayers challenged with TNFα showed that EC pre-treatment with OxPAPC significantly attenuated TNFα-induced EC permeability increase. Experiments with siRNA-induced knockdown of FPR receptors showed that knockdown of FPR2/ALX, but not FPR1 or FPR3, suppressed OxPAPC-induced barrier-protective effect ( Figure 4A ). Visualization of TNFα-induced EC barrier dysfunction using fluorescein isothiocyanate-avidin as a tracer showed pronounced increase in green fluorescence reflecting increased penetration of fluorescein isothiocyanate-avidin through EC monolayers and immobilization on the substrate underlying EC monolayers. OxPAPC caused pronounced protective effect against TNFα-induced permeability, which was attenuated by pre-treatment with FPR2/ALX inhibitor ( Figure 4B) .
Time-resolved analysis of EC permeability using TER measurements showed that pre-treatment with OxPAPC caused TER elevation, which decreased after TNFα challenge, but remained at higher levels even 15 to 20 hours after TNFα challenge in comparison to EC exposed to TNFα without OxPAPC pre-treatment. Pharmacological inhibition of FPR by WRW4 did not affect the initial phase of OxPAPC protective response but markedly reduced TER levels at later time points (10-20 hours after TNFα challenge; Figure 4C ).
TNFα-induced sustained EC barrier dysfunction was associated with increased F-actin stress fiber formation and disruption of cell-cell junctions, leading to formation of paracellular gaps observed at later points of TNFα treatment. OxPAPC attenuated TNFα-induced disruption of EC monolayer integrity, but this OxPAPC barrier-protective effect was suppressed by pre-treatment with FPR2/ALX inhibitor ( Figure 4D ).
TNFα triggers EC inflammatory response characterized by activation of NF-κB signaling and expression of EC adhesion molecules ICAM1 and VCAM1. This TNFα effect was inhibited by OxPAPC and LXA4 ( Figure 5A ). Importantly, EC pre-treatment with FPR2/ALX inhibitor WRW4 suppressed anti-inflammatory effect of both, OxPAPC and LXA4. (Figure 5A ). siRNA-induced FPR2/ALX knockdown used as a complementary approach caused similar effect: inhibition of TNFα-induced VCAM1 expression caused by OxPAPC pre-treatment was attenuated in EC with depleted FPR2/ALX Figure 2 . Formyl peptide receptor(FPR) 2/ALX knockdown does not affect barrier-protective effect of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) against thrombin-induced permeability. Pulmonary endothelial cell (EC) transfected with nonspecific or FPR1-, FPR2/ALX-, or FPR3-specific small interfering RNA were treated with thrombin (0.5 U/mL) with or without OxPAPC pretreatment (15 µg/mL, 30 min). A, Analysis of EC permeability for macromolecules using fluorescein isothiocyanate (FITC)-labeled avidin as a tracer; n=6, *P<0.01 vs thrombin alone. B, Myosin light chain (MLC) di-phosphorylation was evaluated using phospho-MLC-specific antibody in control, thrombin, or OxPAPC-treated EC. C, Effects of OxPAPC and lipoxin A4 (LXA4; 100 nmol/L) on thrombin-induced MLC phosphorylation were evaluated by Western blotting. Probing for β-tubulin was used as a normalization control. Numeric data depict results of quantitative densitometry; n=4; P<0.05 vs thrombin alone. nsRNA indicates nonspecific RNA; and XperT, express permeability testing assay.
( Figure 5B ). Inset depicts siRNA-induced FPR2/ALX protein depletion verified by Western blot. Pharmacological inhibition of FPR2/ALX also attenuated inhibitory effects of OxPAPC and LXA4 on TNFα-induced secretion of soluble ICAM1 by pulmonary EC, which was measured 20 hours after TNFα addition ( Figure 5C ).
EC Exposure to OxPAPC Causes LXA4 Accumulation in the Conditioned Medium
The data described above show involvement of lipoxin receptor FPR2/ALX in protective effects of OxPAPC against TNFα-induced EC inflammation and barrier dysfunction. One potential explanation of this effect is an induction of LXA4 by cell exposure to OxPAPC. This possibility was directly investigated in the following studies. LXA4 levels in the conditioned culture medium from EC exposed to OxPAPC were measured using ELISA. Treatment of pulmonary EC with OxPAPC significantly increased LXA4 levels in a timedependent manner with maximal increase by 24 hours of OxPAPC exposure ( Figure 6A ). Importantly, EC incubation with oxidation-resistant PAPC analog, DMPC, did not result in LXA4 production. EC pre-incubation with lipopolysaccharide did not result in considerable elevation of LXA4 production, whereas stimulation of lipopolysaccharide-challenged cells with OxPAPC administered 1 hour after lipopolysaccharide addition caused a similar increase in LXA4 levels as treatment with OxPAPC alone ( Figure 6B ). The levels of LXA4 in conditioned medium of OxPAPC-treated EC increased with time of OxPAPC incubation, whereas addition of DMPC did not cause any LXA4 elevation.
One described mechanism of LXA4 production is cooperative interaction between myeloid and nonmyeloid cells differently expressing 15-lipoxygenase, 5-lipoxygenase, and epoxide hydrolase activities required for LXA4 synthesis. 40 Published studies suggest that LXA4 production in vivo can be enhanced by EC interaction with leukocytes.
19, 41 We next tested whether OxPAPC-induced LXA4 generation is further enhanced by EC coculture with neutrophils (polymorphonuclear leukocyte [PMN] ). EC monolayers were treated with vehicle or lipopolysaccharide for 1 hour before addition of PMN and OxPAPC. Analysis of LXA4 levels in conditioned medium after 6 hours of EC-PMN coculture did not reveal significant difference between EC-PMN coculture and EC cultured without PMN ( Figure 6C) .
Analysis of LXA4 levels in the lung tissue extracts from mice with intratracheal administration of lipopolysaccharide, with or without intravenous injection of OxPAPC, showed significant increase of LXA4 levels after 24 hours of OxPAPC administration while lipopolysaccharide group did not show LXA4 increase above control levels ( Figure 6D ). LXA4 induction by OxPAPC was further verified using MS approach described in Methods. MS analysis of the conditioned medium from the EC stimulated with OxPAPC or oxidation-resistant phospholipid, DMPC, confirmed results of ELISA assays. The data showed time-dependent increase in LXA4 generation by EC treated with OxPAPC but not with DMPC ( Figure 6E, left) . Control studies showed that addition of OxPAPC and DMPC in the absence of cells showed marginal increase in LXA4 signal in the cell-free culture medium ( Figure 6E, right) . Furthermore, in agreement with ELISA results, LXA4 was not detected in the conditioned medium from EC stimulated with lipopolysaccharide alone or lipopolysaccharide+DMPC, but LXA4 levels were increased on EC incubation with lipopolysaccharide and OxPAPC ( Figure 6F ). MS profiles (Online Figure III) of the extracts from the medium collected from nonstimulated cells or cells stimulated with DMPC did not show any signal corresponding to LXA4. The used transition for the detection of LXA4 is highly specific (m/z 351>115) and is not characteristic for other naturally occurring products of arachidonic acid oxidation.
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Analysis of OxPAPC-Induced LXA4 Generation
Our data suggest that production of lipoxins is likely to be involved in the sustained anti-inflammatory and potentially proresolving actions of OxPAPC. Canonical biosynthesis pathway of LXA4 involves 15-lipoxygenase. We first tested 15-lipoxygenase expression levels in the human pulmonary EC. Real-time RT-PCR analysis of 15-lipoxygenase mRNA expression in control and OxPAPC-stimulated EC showed that 15-lipoxygenase was not expressed in control EC under nonstimulated conditions, in the presence of OxPAPC (15 or 30 µg/mL; after 1, 6, or 24 hours), or in the presence of DMPC (15 µg/mL, 6 hours). These results are consistent with the lack of basal 15-lipoxygenase expression in human EC reported in previous publication. 43 Furthermore, EC treatment with inhibitors of 15-lipoxygenase and 5-lipoxygenase did not affect OxPAPC protective effects against TNFα-induced EC barrier disruption ( Figure 7A ) and interleukin-8 production ( Figure 7B ). EC pre-incubation with lipoxygenase-5 and lipoxygenase-15 inhibitors did not affect OxPAPC-induced elevation of LXA4 signal in EC-conditioned medium detected by MS ( Figure 7C ). In contrast, inhibitor of soluble phospholipase type 2 prevented LXA4 accumulation in pre-conditioned medium of OxPAPC-incubated human pulmonary artery ECs.
Role of FPR2/ALX in Anti-Inflammatory and Barrier-Protective Effects of OxPAPC in the Animal Model of Acute Lung Injury
Our findings from cell culture experiments showing involvement of FPR2/ALX in OxPAPC anti-inflammatory effects and the data showing OxPAPC-induced elevation of LXA4 prompted us to test the hypothesis that LXA4 induction may be involved in OxPAPC-induced recovery of acute lung injury caused by Gram-negative pathogens. In the following experiments, C57Bl mice challenged with lipopolysaccharide (intratracheally) were treated with OxPAPC, with or without FPR2/ALX inhibitor WRW4 (2 mg/kg IV, 15 minutes before OxPAPC), and lung injury was evaluated 24 hours after lipopolysaccharide challenge. Lipopolysaccharide caused significant increase in the total cell counts and protein concentration in BAL samples, which was significantly attenuated by OxPAPC administration ( Figure 8A ). Treatment with FPR2/ ALX inhibitor suppressed protective effects of OxPAPC.
The role of FPR2/ALX signaling in anti-inflammatory effects of OxPAPC was further investigated using genetic model of mFPR2
−/− knockout mice described previously. 33 We evaluated the magnitude of lung injury in control and FPR −/− mice, which was analyzed 24 hours after lipopolysaccharide administration. mFPR2
−/− mice and matching controls developed similar levels of lung injury after 24 hours of lipopolysaccharide challenge reflected by increased cell counts and protein Effects of FPR2 ablation on protective effects of OxPAPC against the lung vascular leak caused by lipopolysaccharide were further assessed by visualization of Evans blue extravasation into the lung tissue. In agreement with previous reports, OxPAPC intravenous administration significantly reduced lipopolysaccharide-induced Evans blue accumulation in the lung parenchyma. However, this protective effect of OxPAPC was suppressed in mFPR2 −/− mice ( Figure 8C ). Analysis of other biochemical readouts of lung injury and inflammation showed marked suppression of the lipopolysaccharide-induced ICAM1 expression in the lung tissue, and this effect of OxPAPC treatment was attenuated in mFPR2 −/− mice ( Figure 8D ). We also found that OxPAPC suppressed OxPAPC-induced decreases in soluble ICAM1 and TNFα levels in lung BAL samples from mFPR2 −/− mice challenged with lipopolysaccharide ( Figure 8E ).
Discussion
Anti-inflammatory effects of OxPAPC in the models of lung injury caused by cell wall components from Gram-negative and Gram-positive bacteria, CpG DNA, lung injury associated with necrotizing pancreatitis, and other conditions associated with activaion of TLR signaling and innate immune response are well recognized. 8, 9, 11, [44] [45] [46] These effects have been previously associated with OxPAPC-directed attenuation of TLR signaling in response to bacterial pathogens and other pathogen-associated molecular patterns.
1 Importantly, to exclude direct inhibition of TLRs by OxPAPC, in the animal model, we performed intravenous injection of OxPAPC 5 hours after intratracheal instillation of lipopolysaccharide. Therefore, OxPAPC protective effects against TNFα-and lipopolysaccharide-induced inflammation and EC barrier disruption observed in this study suggest the presence of other TLR-independent mechanisms. Our data show that OxPAPC also attenuated EC inflammatory and permeability response to TNFα, which is not mediated by the TLR pathway. Interestingly, the OxPAPC protective effects were inhibited by knockdown or pharmacological inhibition of the LXA4 receptor FPR2/ALX. These results strongly suggest that OxPAPC inhibitory effect on TNFα-induced EC inflammation is mediated by TLR-independent mechanism. This study demonstrates for the first time an alternative, TLR-independent anti-inflammatory effects of OxPAPC in the models of TNFα and lipopolysaccharide-induced inflammation. We describe here the OxPAPC-induced activation of proresolution pathway: stimulation of LXA4 production by OxPAPC-exposed pulmonary EC and FPR2/ALX receptordependent suppression of lung inflammation and improvement of endothelial dysfunction caused by inflammatory agents.
The canonical pathway of LXA4 production involves conversion of LXA4 precursor, arachidonic acid to LXA4. This process involves sequential combination of 15-lipoxygenase, Figure 7 . Analysis of oxidized 1-palmitoyl-2-arachidonoylsn-glycero-3-phosphocholine (OxPAPC)-induced lipoxin A4 (LXA4) generation. Endothelial cells (EC) were pre-incubated with 5-lipoxygenase (LO) or 15-LO inhibitor for 1 h followed by TNFα (tumor necrosis factor-α) challenge (20 ng/mL, marked by second arrow) with or without OxPAPC pre-treatment (15 µg/ mL, marked by first arrow). A, Transendothelial electric resistance measurements reflecting changes in EC permeability were performed for 25-h time period. B, Interleukin-8 (IL-8) accumulation in EC-conditioned medium after stimulations was measured using ELISA assay. C, EC pre-treated with sPLA2 (secretory type II phospholipase A2), 15-LO, or 5-LO inhibitors were incubated with OxPAPC or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC; 15 µg/mL), and LXA4 accumulation in conditioned medium was measured by mass spectrometry; n=3, *P<0.05; LOi indicates lipoxygenase inhibitor; and ND, no difference. Culture medium with addition of OxPAPC, DMPC, or LXA4 without exposure to the cells was used as an additional control. F, Mass spectrometry analysis of LXA4 in the conditioned medium of EC stimulated with LPS, LPS+OxPAPC, or LPS+DMPC. Cells were incubated with agonists for 6 or 24 h. LXA4 was detected in the conditioned medium; n=3, *P<0.05 vs LPS alone. HPAEC indicates human pulmonary artery EC; and ND indicates no difference. 5-lipoxygenase, and epoxide hydrolase activities 40 expressed by different cell types and therefore requiring cell-cell interactions at sites of inflammation. Although LXA4 is present in low abundance during the initiation of acute inflammation, their levels increase substantially during resolution. [47] [48] [49] LXA4, in turn, exhibits multifacet modalities in suppressing inflammation and promoting lung repair, 19 including a novel mechanism for control of vascular endothelial inflammation by changes in lung micromechanics recently described by our group. 18 Interaction of PMN with resident cells, such as EC, during inflammation is a previously described model to induce LXA4 production. 15, 47 Although this is the case generally, there are several reports documenting single cell types producing lipoxins, such as human macrophages and dendritic cells, 50 primed human peripheral blood neutrophils, 17 and macrophages. 51 EC pre-incubation with lipopolysaccharide for different time periods in this study neither induced LXA4 production by pulmonary EC on its own nor it affected LXA4 induction caused by EC incubation with OxPAPC ( Figure 6 ). We also did not observe LXA4 upregulation in the lipopolysaccharide-treated lungs 24 hours after lipopolysaccharide administration although OxPAPC injection in lipopolysaccharide-treated mice caused the LXA4 increase. This result may be explained by short time period of our experiment. LXA4 induction also depended on phospholipid oxidation because EC exposure to oxidation-resistant phospholipid DMPC did not induce LXA4 production.
The data show that 15-lipoxygenase and 5-lipoxygenase did not affect OxPAPC-induced LXA4 production while inhibitor of soluble PLA2 suppressed LXA4 accumulation in conditioned medium and attenuated OxPAPC anti-inflammatory effect. Interestingly, CYP450 epoxygenase inhibitor also partially blocked OxPAPC-induced LXA4 accumulation detected by MS (data not shown). These data indicate additional involvement of CYP450 in the LXA4 production from OxPAPC. Altogether, our results strongly suggest 15-LOXindependent, sPLA2-dependent mechanism of LXA4 production by pulmonary EC induced by OxPAPC. Further studies are warranted to delineate a precise role of enzymatic and nonenzymatic OxPAPC conversions mediated by EC and resulting in accumulation of LXA4 in culture medium.
From biochemical point of view, PAPC oxidation by air causes formation of epoxy derivatives of PAPC on their arachidonoyl moiety. But on addition of OxPAPC to cell culture or in the animal experiments, such oxidized (epoxy) lipids are likely to undergo metabolic changes. Then, simultaneous action of cellular epoxide hydrolases and the nonenzymatic formation of intermediate peroxi-intermediates may result in the formation of LXA4-type structures from air-oxidized PAPC and explain lipoxygenase-independent LXA4 formation.
Our results show somewhat higher estimation of LXA4 signal by the LC/MS/MS (liquid chromatography tandem mass spectrometry) method as compared with ELISA results. First, these differences may be because of variances in experimental conditions, such as cell to culture medium ratio and different batches of human pulmonary EC used for ELISA and MS experiments. LC/MS/MS methodology used in this study allows for highly specific detection of the LXA4 in biological fluids. The extracts of the pre-conditioned medium from nonstimulated and DMPC-stimulated cells do not show signal corresponding to LXA4. The used transition for the detection of LXA4 is unique (m/z 351>115) and is not characteristic for the most known products of arachidonic acid oxidation 42 and even for the LXB4. However, we acknowledge one potential limitation of this study. We cannot rule out that oxygenation of PAPC may result in the formation of stereo-and OH-group positional isomers of LXA4 which will be more challenging to separate using our current technique and which could mask and overlay the true LXA4. These factors may result in potential LXA4 overestimation by MS. Our future work will address such a possibility.
In summary, this study shows a novel anti-inflammatory effect of OxPAPC in cell and animal models of acute lung injury caused by bacterial pathogen and inflammatory cytokine, which is associated with OxPAPC-induced formation of LXA4 and activation of FPR2/ALX receptor. These results demonstrate a new way of lipid program switch triggered by oxidized phospholipids generated as a result of oxidative stress during lung inflammation or injury. We speculate that production of anti-inflammatory lipid mediators by canonical pathway of lipoxin synthesis during lipid mediator program switch 47 at advanced stage of inflammation may be accelerated in the presence of OxPAPC. Beneficial role of LXA4-FPR2/ALX signaling has been also shown in other pathological conditions. FPR2/ALX-LXA4 axis controls vascular inflammatory responses during cerebral ischemia/reperfusion, and induction of LXA4 may be beneficial for patients experiencing stroke. 52 Induction of LXA4 reduces capillary congestion in malaria model 53 and may also influence the clinical management of patients with trauma because higher lipoxin/resolvin scores have been reported in patients with uncomplicated recoveries. 54 The results of this study strongly suggest that phospholipid oxidation induced by inflammatory insults may represent a built-in mechanism of body recovery after injury. Therefore, the induction of lipoxin production by OxPAPC described in this study may have a broader impact on the outcome of other acute and chronic inflammatory conditions and implication in development of future therapies.
